Mentari Therapeutics (MTRI) closed at $15.61 on November 11, 2026, up 27.9% from the previous close, on volume of 59,301 shares (30-day average 54,608).
Data as of November 11, 2026.
No headlines found.
Mentari Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire (Mon, 9-Nov 8:00 AM ET)
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities focus on therapeutic candidates targeting PACAP and CGRP-related mechanisms for migraine prevention.
Mentari Therapeutics trades on the NASDAQ stock market under the symbol MTRI.
As of November 12, 2026, MTRI stock price climbed to $18.79 with 142,822 million shares trading.
MTRI has a market cap of $1.10 billion. This is considered a Small Cap stock.
MTRI support price is $12.75 and resistance is $18.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MTRI shares will trade within this expected range on the day.
